Twist Bioscience Corp (TWST) company profile
Close on Nov 16, 2026Market cap $6.59BP/E –Yield –
About Twist Bioscience
Biological Products, (No Diagnostic Substances), SIC 2836
Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA using a proprietary silicon chip platform. Its primary offerings comprise synthetic biology tools—such as clonal genes, gene fragments, oligo pools, and IgG proteins—and next-generation sequencing products, including target enrichment panels and library preparation kits. In addition, the company provides biopharma solutions for antibody discovery, optimization, and characterization. It sells products and services to biopharmaceutical companies, diagnostic laboratories, agricultural enterprises, chemical manufacturers, and academic research institutions.
The company serves more than 3,800 customers worldwide across the healthcare, industrial chemicals, academic, and agricultural sectors. Twist Bioscience maintains manufacturing and operations facilities in South San Francisco, California, and Wilsonville, Oregon, supported by commercial personnel and consultants in Europe and Asia. Its principal manufacturing and operational base is located in South San Francisco, California.
Summary of the business section of Twist Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Twist Bioscience Corp
- Founded
- 2013
- Headquarters
- South San Francisco, CA
- Address
- 681 Gateway Blvd. 94080
- Phone
- (800) 719-0671
- Website
- twistbioscience.com
- Employees
- 979, Sep 30, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- TWST
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2018
- Shares outstanding
- 63M, Jul 29, 2026
- Public float
- $2.32B, Mar 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1581280
- CUSIP
- 90184D100
- ISIN
- US90184D1000
- FIGI
- BBG006KDCHJ4
- Share class FIGI
- BBG006KDCHK2
- LEI
- 549300T23BL59LCOH584
- EIN
- 46-2058888
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Emily M. Leproust | Chief Executive Officer, Director | 656,044 |
| Patrick John Finn | President and COO | 233,913 |
| Paula Green | SVP of Human Resources | 126,054 |
| Adam Laponis | Chief Financial Officer | 124,860 |
| Dennis Cho | See Remarks | 85,665 |
| Robert F. Werner | Chief Accounting Officer | 51,208 |
| Katryn Blake | Director | 17,208 |
| Robert Chess | Director | 63,612 |
| Melissa A. Starovasnik | Director | 22,222 |
| Jan Johannessen | Director | 29,754 |
| Keith Crandell | Director | 103,618 |
| Robert P. Ragusa | Director | 28,983 |
| Nelson Chan | Director | 33,251 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.78M | $928.13K | $4.80M | $37 | $119 |
| FY2024 | $7.62M | $24.98M | $2.68M | $59 | $116 |
| FY2023 | $8.00M | $3.22M | $3.09M | $27 | $95 |
| FY2022 | $5.92M | -$15.04M | $2.48M | $46 | $90 |
| FY2021 | $1.28M | $18.05M | $728.15K | $141 | $120 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Emily M. Leproust, Ph.D. Chief Executive Officer and Chair of the Board | $720.00K | $12.00M | $932.92K | $130.52K | $13.78M | +81% |
| Adam Laponis Chief Financial Officer | $490.00K | $3.37M | $349.20K | $11.49K | $4.22M | -16% |
| Patrick Finn, Ph.D. President and Chief Operating Officer | $563.00K | $6.75M | $583.59K | $127.40K | $8.02M | +108% |
| Paula Green Senior Vice President of Human Resources | $400.00K | $2.57M | $259.14K | $119.18K | $3.35M | +67% |
| Dennis Cho Chief Legal Officer and Corporate Secretary | $449.00K | $2.87M | $290.89K | $9.13K | $3.62M | +101% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 1, 2018
- Offer price
- $14.00
- Securities offered
- 5,000,000
- Gross proceeds
- $70.00M
- Exchange
- Nasdaq
- First trading day
- Oct 31, 2018
- First-day close
- $14.000.0%
- Lock-up ends (est.)
- Apr 29, 2019
“The initial public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 979 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 9, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 1, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 25, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?